Literature DB >> 7529459

Effects of tiludronate on bone mass, structure, and turnover at the epiphyseal, primary, and secondary spongiosa in the proximal tibia of growing rats after sciatic neurectomy.

H Murakami1, T Nakamura, H Tsurukami, M Abe, A Barbier, K Suzuki.   

Abstract

To evaluate the effects of tiludronate on the mass, structure, and turnover of cancellous bone regions in immobilized rat tibiae, we performed a 4 week dosing experiment. The right hindlimbs of 84 Sprague-Dawley rats (5 weeks old) wee neurectomized or sham operated. Animals were assigned to seven groups (n = 12 each); group 1 was sham operated, and groups 2-7 were neurectomized. Groups 1 and 2 were given vehicle only (distilled water), and groups 3, 4, and 5 were given tiludronate orally at doses of 25, 50, and 100 mg/kg body weight (BW)/day, respectively, throughout the experimental period. Group 6 was given 100 mg/kg BW/day of the agent for the first 2 weeks only, and group 7 received vehicle only for the first 2 weeks and then 100 mg/kg BW/day of the agent for the last 2 weeks. After tetracycline labeling was performed, the right tibiae were removed from the animals and processed to yield undecalcified sections. Histomorphometry was performed in the epiphyseal, primary, and secondary spongiosa of the proximal tibia. In group 2, trabecular bone volume (BV/TV) and trabecular number (Tb.N) were significantly decreased in the primary and secondary spongiosae, but this did not occur in the epiphyseal spongiosa. Osteoid surface (OS/BS) was decreased and osteoclast surface (Oc.S/BS) was increased in the secondary spongiosa. Tiludronate increased BV/TV and Tb.N in the primary spongiosa by reducing the values for the parameters of osteoclast surface (Oc.S/BS) and osteoclast number (Oc.N/BS). Osteoid surface in this region was not decreased by the agent. In groups 4 and 5, tiludronate prevented bone loss in the secondary spongiosa by reducing both OS/BS and Oc.S/BS. In group 6, BV/TV in the primary spongiosa was maintained at the level of group 1, but Oc.S/BS and Oc.N/BS were elevated. In the secondary spongiosa, bone mass was preserved and the reduction in these parameters was maintained. In group 7, however, BV/TV was increased in the primary spongiosa as a result of a reduction in osteoclastic resorption; in the secondary spongiosa, however, BV/TV was decreased and trabecular turnover was not reduced at the end of the experiment in these growing animals. Mineral apposition rates were not reduced by tiludronate. This study clearly demonstrated that this agent prevented immobilization bone loss by inhibiting resorption.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7529459     DOI: 10.1002/jbmr.5650090906

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  13 in total

1.  Local bone turnover in the metaphysis of the proximal tibia and the lumbar vertebra during the early periods after ovariectomy in rats.

Authors:  M Yamaura; T Nakamura; H Tsurukami; A Hijioka; K Narusawa; H Ohnishi; T Ohta; K Hosoda
Journal:  Calcif Tissue Int       Date:  1996-01       Impact factor: 4.333

2.  Immobilization as the pathogenesis of osteoporosis: experimental and clinical studies.

Authors:  H Norimatsu; S Mori; J Kawanishi; Y Kaji; J Li
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

3.  Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation.

Authors:  A Montero; Y Okada; M Tomita; M Ito; H Tsurukami; T Nakamura; T Doetschman; J D Coffin; M M Hurley
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

4.  Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.

Authors:  Marilena Tauro; Gemma Shay; Samer S Sansil; Antonio Laghezza; Paolo Tortorella; Anthony M Neuger; Hatem Soliman; Conor C Lynch
Journal:  Mol Cancer Ther       Date:  2017-01-09       Impact factor: 6.261

5.  Combination therapy with dexamethasone and osteoprotegerin protects against arthritis-induced bone alterations in antigen-induced arthritis of the rat.

Authors:  P Oelzner; S Fleissner-Richter; R Bräuer; G Hein; G Wolf; T Neumann
Journal:  Inflamm Res       Date:  2010-03-20       Impact factor: 4.575

6.  Effects of risedronate on femoral bone mineral density and bone strength in sciatic neurectomized young rats.

Authors:  Jun Iwamoto; Azusa Seki; Tsuyoshi Takeda; Yoshihiro Sato; Harumoto Yamada
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

7.  Paradoxical response to mechanical unloading in bone loss, microarchitecture, and bone turnover markers.

Authors:  Xiaodi Sun; Kaiyun Yang; Chune Wang; Sensen Cao; Mackenzie Merritt; Yingwei Hu; Xin Xu
Journal:  Int J Med Sci       Date:  2015-03-01       Impact factor: 3.738

8.  1,25-Dihydroxyvitamin D3 prevents bone loss of the secondary spongiosa in arthritic rats by an increase of bone formation and mineralization and inhibition of bone resorption.

Authors:  Peter Oelzner; Peter K Petrow; Gunter Wolf; Rolf Bräuer
Journal:  BMC Musculoskelet Disord       Date:  2014-10-14       Impact factor: 2.362

Review 9.  A Systematic Review of Animal Models of Disuse-Induced Bone Loss.

Authors:  Annemarie Brüel; Jesper Skovhus Thomsen; Mikkel Bo Brent
Journal:  Calcif Tissue Int       Date:  2021-01-01       Impact factor: 4.333

10.  Stimulation of Osteogenesis in Bone Defects Implanted with Biodegradable Hydroxyapatite Composed of Rod-Shaped Particles under Mechanical Unloading.

Authors:  Tohru Ikeda; Yoshinori Gonda; Eri Tatsukawa; Yasuaki Shibata; Masanobu Kamitakahara; Takatoshi Okuda; Ikuho Yonezawa; Hisashi Kurosawa; Koji Ioku
Journal:  Acta Histochem Cytochem       Date:  2012-09-08       Impact factor: 1.938

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.